TB-500 Dosage Guide: What the Research Shows (2026)

Almost everything sold as “TB-500” online is actually a different peptide than the one in the studies people cite, and the vendors selling it are quietly betting you’ll never notice.

That’s not a typo. It’s the single most important fact about this compound, and almost no one writing about it will tell you.

So this guide does. What TB-500 actually is, how the research dosing protocols are structured, the half-life that makes its schedule unusual, and the buyer trap that catches nearly everyone. By the end you’ll understand this peptide better than 95% of the people selling it.

For in vitro laboratory research and educational use only. Not medical advice, not a recommendation for human use.

The 30-Second Answer

What TB-500 Actually Is (And the Trap in the Name)

Here’s where the confusion starts, and where most articles get it wrong.

Your body makes a natural protein called Thymosin Beta-4 (Tβ4), a 43-amino-acid molecule involved in tissue repair, cell migration, and inflammation. TB-500 is not that protein. It’s a synthetic 17-amino-acid fragment containing the central actin-binding motif (the LKKTETQ sequence) of Tβ4. The fragment reproduces the cytoskeletal and cell-migration effects of the parent protein, but it does not carry all of the parent’s other functions.

Why does this matter to you as a buyer? Two reasons, and both cost people money.

First, almost all the human clinical evidence is on full-length Tβ4, not the TB-500 fragment. The ulcer trials, the eye-disease trials, those used the complete protein. Treating the fragment and the full protein as identical is an assumption the research community makes routinely, but it has never been proven. Anyone citing “human trials” for TB-500 specifically is stretching the truth.

Second, vendors blur this line constantly. Some sell full-length Tβ4 as “TB-500.” Some sell the fragment. The label rarely tells you which. That ambiguity is the first reason a third-party Certificate of Analysis matters so much here, more on that below.

How TB-500 Works

The mechanism is genuinely elegant, and it explains the unusual dosing schedule.

TB-500 binds and sequesters actin, a protein essential for cell movement. By regulating the actin pool, it promotes cell migration, the process of getting repair cells to an injury site. In preclinical models it also upregulates actin expression, promotes angiogenesis (new blood vessel formation), and dampens inflammation.

The key word is systemic. Unlike a compound that acts locally where you put it, TB-500’s mechanism requires tissue saturation throughout the body. Repair cells need to migrate to wherever the damage is, which means the compound has to reach therapeutic levels everywhere. That single fact drives the entire loading-then-maintenance dosing structure researchers use. You can’t just dose the injury. You have to saturate the system first.

In animal studies, this translated to accelerated wound healing, cardiac tissue repair, better collagen deposition, and faster blood-vessel growth at repair sites. The catch, and it’s a real one: these are animal models. The fragment itself has no completed human clinical trials.

The Half-Life That Explains Everything

This is the detail that makes TB-500 different from peptides like BPC-157, and it’s why the dosing schedule looks the way it does.

In rats, the plasma half-life after subcutaneous or intramuscular injection runs roughly two to three hours. But here’s the interesting part: the downstream effects on cells in the repair zone last far longer than the compound stays in the blood. Research protocols use a twice-weekly loading schedule rather than daily dosing, which tells you the biologically relevant tissue levels persist for something like three to four days per injection.

In plain terms: TB-500 triggers a healing cascade that keeps running after the peptide itself has cleared. You’re not topping up a drug that drains hourly. You’re pulsing a signal that echoes for days. That’s why nobody injects this daily, and why anyone telling you to is working from a misunderstanding of how it behaves.

TB-500 Research Dosing Protocols

Let me be direct about what this section is. These are dosing patterns reported in animal research and used in the research-compound community. They are not treatment recommendations, and TB-500 is not approved for human use. With that stated plainly, here’s how the protocols are structured.

The two-phase structure. Almost every TB-500 research protocol follows the same shape:

• Loading phase: more frequent dosing to establish baseline tissue levels across the body, typically twice weekly for the first 4 to 6 weeks.
• Maintenance phase: less frequent dosing to sustain those levels, typically once weekly thereafter.

This structure exists because of the systemic-saturation point above. Starting with maintenance doses alone would delay any measurable effect, because the body hasn’t reached baseline saturation yet.

Animal-model dose ranges. In published preclinical work, systemic doses span roughly 0.1 to 10 mg/kg depending on the animal model and the injury studied, delivered subcutaneously or intraperitoneally. Animal doses do not translate directly to any other context, and the wide range reflects how varied the research models are.

Duration. Acute-injury research protocols run a couple of weeks. Chronic or connective-tissue models run longer. The loading-then-maintenance arc usually spans 4 to 6 weeks of loading before dropping to maintenance.

Route matters, and oral doesn’t work. Published protocols use subcutaneous, intramuscular, intraperitoneal, or topical administration. There is no reliable evidence of oral activity for TB-500. Unlike BPC-157, it is not characterized as resistant to stomach enzymes, and oral bioavailability has never been demonstrated. So if you see “TB-500 capsules” or “oral TB-500” for sale, understand that the research doesn’t support that route working at all. That’s the second major buyer trap.

TB-500 and BPC-157: Why They’re Studied Together

You’ll almost never see TB-500 discussed alone. It’s half of the most popular pairing in the research-peptide world, often nicknamed the “Wolverine Stack.”

The logic is complementary mechanisms. BPC-157 is a 15-amino-acid fragment from gastric juice, associated with growth-factor and angiogenesis pathways, and notably stable enough to survive the stomach. TB-500 is the actin-binding, cell-migration fragment. Researchers pair them because they approach tissue repair from different biological angles, one supporting blood-vessel and growth-factor activity, the other driving the cell-migration that brings repair cells to the site.

One important contrast: BPC-157 has at least some evidence of oral stability. TB-500 does not. So in the stack, they are not interchangeable and not dosed the same way.

If recovery research is your focus, see our best place to buy BPC-157 guide for the other half of the pairing, and the peptide finder to compare both against your goal.

The FDA Status You Should Know

TB-500’s legal status is shifting, so here’s the current picture.

TB-500 is classified by the FDA as a Category 2 substance, and it is prohibited by WADA (the World Anti-Doping Agency) at all times for athletes. As of 2026, a reclassification process is in motion, but until a formal FDA rule is finalized, it remains Category 2 under current law. This is exactly why TB-500 is sold strictly as a research compound, not a supplement or drug, and why responsible sourcing and clear research-use framing matter.

How to Buy TB-500 Without Getting Burned

Given everything above, the buyer checklist for TB-500 is stricter than for most peptides. Three specific traps to avoid:

The relabeling trap. Because “TB-500” and full-length Tβ4 get used interchangeably, you need a Certificate of Analysis that confirms what’s actually in the vial. A third-party COA with mass spectrometry confirms the compound’s identity, not just its purity.

The oral trap. Skip any “TB-500 capsules” or oral version. The research doesn’t support oral activity. It’s a format that sounds convenient and can’t deliver.

The purity trap. Like all research peptides, independent testing has found a large share of products underdosed or mislabeled. Buy only from vendors with batch-specific, third-party COAs you can verify against your vial’s lot number.

For vendors that meet that bar, with verifiable third-party testing rather than in-house claims, see our guide to the best peptide vendors of 2026. And once you’ve got a vial, our peptide reconstitution calculator handles the dosing math.

The Bottom Line

TB-500 is one of the most interesting recovery compounds in peptide research, and one of the most misunderstood. The mechanism is real and elegant: regulate actin, drive cell migration, saturate the system, and trigger a healing cascade that outlasts the compound itself. That’s why it’s dosed in pulses, not daily.

But the name hides a trap. Most human evidence is on the full protein, not the fragment you’re buying, and vendors exploit that gray zone constantly. Add the oral-version scam and the industry-wide purity problem, and the lesson is simple: understand what TB-500 actually is, demand a third-party COA that confirms it, and never trust a format the research doesn’t support.

Know the compound, verify the vial, and you’re already ahead of nearly everyone in this market.

This guide is for in vitro laboratory research and educational purposes only. TB-500 is a research compound, not approved by the FDA for human or animal consumption, currently classified Category 2 and prohibited by WADA. Nothing here is medical advice or a dosing recommendation for human use. Always verify information independently and consult qualified professionals.